ストックスクリーナーアプリを入手
90.73
1.00%
-0.93
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Why Mirum Pharmaceuticals Stock Is Sinking Today - TipRanks
Penn Capital Management Company LLC Sells 34,265 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 40,985 Shares - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 16,515 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 4,732 Shares - MarketBeat
Mirum Pharma’s chief medical officer Quan sells $670k in stock - Investing.com Canada
Mirum Pharmaceuticals Executives Sell Shares - TradingView
Mirum (NASDAQ: MIRM) CFO exercises performance RSUs, sells shares to cover tax withholding - Stock Titan
Mirum (MIRM) CMO exercises performance RSUs, sells 7,287 shares for tax - Stock Titan
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum (MIRM) president sells 16,515 shares, exercises 30,220 RSUs - Stock Titan
Mirum (NASDAQ: MIRM) SVP exercises PRSUs, sells 4,732 shares for taxes - Stock Titan
Mirum (MIRM) CEO sells shares to cover tax from RSU vesting - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) files to sell 7,287 vested RSU shares - Stock Titan
Joanne Quan to Sell 7,287 Mirum Shares (NASDAQ: MIRM) via Morgan Stanley - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) insider files to sell 16,515 shares - Stock Titan
Mirum Pharmaceuticals (MIRM) files Form 144: proposed resale of vested RSUs - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) insider sells vested RSUs totaling multiple transactions - Stock Titan
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli - The Globe and Mail
Mirum completes enrollment & screening in liver disease studies - MSN
Citizens reiterates Mirum Pharmaceuticals stock rating on trial progress - Investing.com
Aquatic Capital Management LLC Boosts Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum completes enrollment in cholestatic pruritus trial By Investing.com - Investing.com India
Trading Recap: Is Mirum Pharmaceuticals Inc a turnaround story2026 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Mirum Pharmaceuticals releases latest announcement details - Traders Union
Saira Ramasastry to sell 2,000 shares via option exercise (NASDAQ: MIRM) - Stock Titan
Mirum completes enrollment in cholestatic pruritus trial - Investing.com
Rare liver disease trial of Mirum itch drug finishes signup - Stock Titan
Algert Global LLC Buys 31,250 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Eventide Asset Management LLC Sells 114,922 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Stock Holdings Reduced by Boone Capital Management LLC - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Aug Patterns: Can Mirum Pharmaceuticals Inc benefit from deglobalization2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals (MIRM)? - simplywall.st
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Mirum Pharmaceuticals (MIRM) president and COO exercises options, lifts stake - Stock Titan
Mirum Pharmaceuticals at Leerink Conference: Strategic Growth Plans By Investing.com - Investing.com Canada
Mirum Pharmaceuticals at Citizens Life Sciences: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (MIRM) and Scalable Risk - Stock Traders Daily
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) earnings expected to grow: What to know ahead of Q4 release - MSN
Mirum’s Brelovitug Phase 3 Milestones Reframe Rare Disease Growth Story - simplywall.st
Mirum Finishes Participant Enrollment and Screening for Liver Disease Research - Bitget
Mirum Completes Enrollment & Screening in Liver Disease Studies - Barchart.com
TD Asset Management Inc Buys Shares of 15,400 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals provides Azure clinical program update for Brelovitug in chronic hepatitis delta virus - marketscreener.com
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus - marketscreener.com
Volatility Watch: Is Mirum Pharmaceuticals Inc a stock for growth or value investorsPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Evercore ISI raises Mirum Pharmaceuticals stock price target on pipeline progress - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Promising Biotech with 35.82% Upside Potential - DirectorsTalk Interviews
William Blair Investment Management LLC Acquires Shares of 313,259 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Vanguard Group Inc. Sells 19,500 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Mirum Pharmaceuticals (MIRM) Is Down 12.8% After Shelf Filing For US$1.3 Billion Equity Issuance - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for MIRM - MarketBeat
1.41%
0.27%
大文字化:
|
ボリューム (24 時間):